Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors
Open Access
- 22 September 2011
- journal article
- Published by Springer Nature in Critical Care
- Vol. 15 (5), R224
- https://doi.org/10.1186/cc10464
Abstract
Introduction: Sepsis-induced immunosuppression may result in death. The mechanisms of immune suppression include loss of macrophage and monocyte expression of the major histocompatibility complex, increased anti-inflammatory cytokine expression and decreased expression of proinflammatory cytokines. In this study, we sought to determine the mechanisms of immune suppression in severe sepsis by repeated detection. Methods: We designed this prospective observational study to measure monocyte human leukocyte antigen (HLA)-DR expression, plasma cytokine levels and cytokine responses on days 1 and 7 in stimulated peripheral blood mononuclear cells (PBMCs) of healthy controls and patients with severe sepsis. Results: Of the 35 enrolled patients, 23 survived for 28 days and 12 died, 6 of whom died within 7 days. Plasma levels of IL-1β, IL-6, IL-10, IL-17, transforming growth factor (TGF)-β1 and TNF-α were higher, but plasma IL-12 level was lower in septic patients than those in controls. Day 1 plasma levels of IL-1β, IL-6, IL-10 and TGF-β1 in nonsurvivors were higher than those in survivors. Day 7 plasma IL-10 levels in nonsurvivors were higher than in survivors. IL-1β response was higher, but IL-12 and TNF-α responses were lower in septic patients than in controls. Day 1 IL-6 response was lower, but day 1 TGF-β1 response was higher in nonsurvivors than in survivors. Plasma IL-6 and IL-10 levels were decreased in survivors after 6 days. IL-6 response was decreased in survivors after 6 days, but IL-12 response was increased. Monocyte percentage was higher, but positive HLA-DR percentage in monocytes and mean fluorescence intensity (MFI) of HLA-DR were lower in septic patients than in controls. MFI of HLA-DR was increased in survivors after 6 days. Conclusions: Monocyte HLA-DR expression and IL-12 response from PBMCs are restored in patients who survive severe sepsis.Keywords
This publication has 32 references indexed in Scilit:
- Transforming growth factor β-1 and interleukin-17 gene transcription in peripheral blood mononuclear cells and the human response to infectionCytokine, 2010
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Critical Care Medicine, 2008
- Cytokine profiles as markers of disease severity in sepsis: a multiplex analysisCritical Care, 2007
- Interleukin-17 Family Members and InflammationImmunity, 2004
- Cytokine Production and Monocyte HLA-DR Expression as Predictors of Outcome for Patients with Community-Acquired Severe InfectionsClinical and Vaccine Immunology, 2004
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003
- Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6Critical Care Medicine, 2000
- Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study GroupPublished by American Medical Association (AMA) ,1994
- APACHE IICritical Care Medicine, 1985